New drug combo tested for Tough-to-Treat breast cancer
NCT ID NCT06764186
Summary
This study is testing whether adding a new drug called capivasertib to an existing hormone therapy (fulvestrant) can help control advanced breast cancer that has specific genetic changes and has started growing again after standard treatments. It will involve about 101 patients in Spain to see how well the combination works, how long it keeps the cancer in check, and what side effects it causes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Alicante, 03010, Spain
-
Research Site
Barcelona, 08003, Spain
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Bilbao (Vizcaya), 48013, Spain
-
Research Site
Córdoba, 14004, Spain
-
Research Site
Donostia / San Sebastian, 20014, Spain
-
Research Site
El Palmar, 30120, Spain
-
Research Site
Girona, 17007, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Oviedo, 33011, Spain
-
Research Site
Palma deMallorca, 07010, Spain
-
Research Site
Salamanca, 37007, Spain
-
Research Site
Santander, 39008, Spain
-
Research Site
Seville, 41073, Spain
-
Research Site
Valencia, 46026, Spain
-
Research Site
Zaragoza, 50009, Spain
Conditions
Explore the condition pages connected to this study.